[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nrx Pharmaceuticals Inc (NRXP)

Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,180
  • Shares Outstanding, K 33,068
  • Annual Sales, $ 1,230 K
  • Annual Income, $ -28,620 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 2.02
  • Price/Sales 80.44
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 127.90% (-50.41%)
  • Historical Volatility 103.58%
  • IV Percentile 10%
  • IV Rank 15.57%
  • IV High 734.57% on 02/13/26
  • IV Low 16.06% on 09/08/25
  • Expected Move (DTE 13) 0.43 (14.03%)
  • Put/Call Vol Ratio 2.50
  • Today's Volume 105
  • Volume Avg (30-Day) 444
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 10,750
  • Open Int (30-Day) 7,569
  • Expected Range 2.66 to 3.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.00
  • Number of Estimates 2
  • High Estimate $0.01
  • Low Estimate $-0.02
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +46.45%
on 04/07/26
3.29 -6.08%
on 04/21/26
+0.93 (+43.06%)
since 04/01/26
3-Month
1.62 +90.74%
on 03/09/26
3.29 -6.08%
on 04/21/26
+0.99 (+47.14%)
since 01/30/26
52-Week
1.62 +90.74%
on 03/09/26
3.84 -19.53%
on 10/07/25
+1.01 (+48.56%)
since 05/01/25

Most Recent Stories

More News
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide

NEW YORK, NY / ACCESS Newswire / May 1, 2026 / New to The Street, one of the longest-running business television brands, today announced the nationwide broadcast of Show #748 airing Saturday, May 2 at...

RDZN : 2.22 (-2.20%)
SNYR : 0.3200 (+2.70%)
IGC : 0.3349 (+4.79%)
VTIX : 3.70 (+7.25%)
NRXP : 3.09 (+3.69%)
MDCX : 0.2853 (+0.96%)
YYGH : 0.8504 (-14.11%)
DVLT : 0.7438 (+2.48%)
CISO : 0.2755 (+5.96%)
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global

Sponsored Programming Supported by Commercials from Medicus Pharma (NASDAQ:MDCX), IGC Pharma (NYSE American:IGC), Roadzen (NASDAQ:RDZN), and Lantern Pharma (NASDAQ:LTRN)

RDZN : 2.22 (-2.20%)
IGC : 0.3349 (+4.79%)
LTRN : 2.12 (+3.41%)
NRXP : 3.09 (+3.69%)
MDCX : 0.2853 (+0.96%)
CISO : 0.2755 (+5.96%)
NRx Pharmaceuticals (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a positive Discipline Review Letter from the FDA Office of Generic Drugs covering quality-related aspects of its ketamine ANDA, with only minor...

NRXP : 3.09 (+3.69%)
BMWYY : 29.2000 (+4.58%)
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

NRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only “Minor” administrative changes NRx conducted a meeting with leadership of the FDA Office...

NRXP : 3.09 (+3.69%)
NRx Pharmaceuticals (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development

NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster...

NRXP : 3.09 (+3.69%)
BMWYY : 29.2000 (+4.58%)
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026. The order directs acceleration of research and lowered barriers to approvals of...

NRXP : 3.09 (+3.69%)
NRx Pharmaceuticals (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research...

NRXP : 3.09 (+3.69%)
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve as...

NRXP : 3.09 (+3.69%)
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch

NRx Pharmaceuticals (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced the appointment of Glenn Tyson as its first Chief...

NRXP : 3.09 (+3.69%)
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer

Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in this...

NRXP : 3.09 (+3.69%)

Business Summary

NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.

See More

Key Turning Points

3rd Resistance Point 3.35
2nd Resistance Point 3.22
1st Resistance Point 3.16
Last Price 3.09
1st Support Level 2.97
2nd Support Level 2.84
3rd Support Level 2.78

See More

52-Week High 3.84
Last Price 3.09
Fibonacci 61.8% 2.99
Fibonacci 50% 2.73
Fibonacci 38.2% 2.47
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.